China Pharma Univ. ENPP1 compound A25

China Pharma Univ. ENPP1 compound A25: sourced facts only. name: "A25 is a potent and selective ENPP1 inhibitor featuring a novel pyrrolo[1',2':1,6]pyrimido[5,4-c]pyridazin-6(5H)-one core scaffold." [PMID:42189583]; target: "A25 is a potent and selective ENPP1 inhibitor featuring a novel pyrrolo[1',2':1,6]pyrimido[5,4-c]pyridazin-6(5H)-one core scaffold." [PMID:42189583]; developer: "Center of Drug Discovery, State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, China Pharmaceutical University, Nanjing 210009, China." [PMID:42189583]; stage: "In a 4T1 syngeneic mouse model, oral administration of compound A25 demonstrated significant antitumor effects and enhanced the efficacy of both anti-PD-1 antibody and chemotherapy, with good tolerability." [PMID:42189583]